Section 5: Patient Safety and Quality Assurance

5PSQ-062

RALTITREXED AS AN END-OF-LIFE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER

5PSQ-061

DETERMINATION OF GENETIC POLYMORPHISMS OF THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN REAL CLINICAL PRACTICE: POSOLOGICAL INDIVIDUALISATION

5PSQ-060

IMMUNOTHERAPY AND TOXICITY: EXPERIENCE IN A THIRD-LEVEL HOSPITAL

5PSQ-059

CYCLIN DEPENDENT KINASES 4/6 INHIBITORS: NEW OPTIONS IN HR+ HER2- BREAST CANCER

5PSQ-058

MEASURING ADHERENCE TO EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES FOR PATIENTS TREATED WITH TRASTUZUMAB

5PSQ-057

OLAPARIB AND NIRAPARIB SAFETY PROFILE IN THE CLINICAL PRACTICE OF A TERTIARY-LEVEL HOSPITAL

5PSQ-056

SAFETY BETWEEN THE USE OF COMMERCIAL AND GENERIC IMATINIB: IS THE EXCIPIENT RELEVANT?

5PSQ-055

DOES PALBOCICLIB MEAN NEUTROPAENIA?

5PSQ-054

NIVOLUMAB IN LUNG CANCER: FROM WEIGHT-BASED TO FLAT DOSING

5PSQ-053

ADAPTATION OF PROPHYLAXIS AGAINST VARICELLA-ZOSTER VIRUS IN PATIENTS WITH MULTIPLE MYELOMA

5PSQ-052

THE ERROR ROOM: A FUN TRAINING TOOL FOR THE PHARMACEUTICAL CHEMOTHERAPY UNIT

5PSQ-051

ANALYSIS OF CARDIOVASCULAR EVENTS ASSOCIATED WITH CARFILZOMIB IN PATIENTS WITH MULTIPLE REFRACTORY MYELOMA

5PSQ-050

TOXICITY WITH 5-FLUOROURACIL AND IRINOTECAN: INTEREST OF GENOTYPING IN PATIENT CARE

5PSQ-049

ATEZOLIZUMAB: EFFICACY AND SAFETY IN ADVANCED NON-SMALL CELL LUNG CANCER

5PSQ-048

REAL-WORLD SAFETY AND TOLERABILITY OF THE RECENTLY COMMERZIALISED PALBOCICLIB

Pages